$ADVM
Adverum Biotechnologies, Inc.

2016 Q3 Form 10-Q Financial Statement

#000156459017022767 Filed on November 08, 2017

View on sec.gov

Income Statement

Concept 2016 Q3
Revenue $395.0K
YoY Change -58.55%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.150M
YoY Change -19.4%
% of Gross Profit
Research & Development $8.360M
YoY Change 11.13%
% of Gross Profit
Depreciation & Amortization $460.0K
YoY Change 91.67%
% of Gross Profit
Operating Expenses $14.90M
YoY Change -1.66%
Operating Profit
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $210.0K
YoY Change 79.49%
Pretax Income -$14.30M
YoY Change 1.56%
Income Tax
% Of Pretax Income
Net Earnings -$14.30M
YoY Change 1.54%
Net Earnings / Revenue -3620.51%
Basic Earnings Per Share
Diluted Earnings Per Share -$345.2K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $231.3M
YoY Change -13.98%
Cash & Equivalents $231.3M
Short-Term Investments
Other Short-Term Assets $2.800M
YoY Change 86.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $235.9M
YoY Change -12.75%
LONG-TERM ASSETS
Property, Plant & Equipment $4.300M
YoY Change 29.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $140.0K
YoY Change 1.45%
Total Long-Term Assets $20.70M
YoY Change 496.89%
TOTAL ASSETS
Total Short-Term Assets $235.9M
Total Long-Term Assets $20.70M
Total Assets $256.6M
YoY Change -6.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.100M
YoY Change 171.69%
Accrued Expenses $5.800M
YoY Change 56.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.60M
YoY Change 63.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $7.700M
YoY Change 54.0%
Total Long-Term Liabilities $7.700M
YoY Change 54.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.60M
Total Long-Term Liabilities $7.700M
Total Liabilities $20.30M
YoY Change 76.54%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $236.2M
YoY Change
Total Liabilities & Shareholders Equity $256.6M
YoY Change -6.29%

Cashflow Statement

Concept 2016 Q3
OPERATING ACTIVITIES
Net Income -$14.30M
YoY Change 1.54%
Depreciation, Depletion And Amortization $460.0K
YoY Change 91.67%
Cash From Operating Activities -$9.640M
YoY Change 4.56%
INVESTING ACTIVITIES
Capital Expenditures -$360.0K
YoY Change -72.52%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$360.0K
YoY Change -103.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -9.640M
Cash From Investing Activities -360.0K
Cash From Financing Activities 0.000
Net Change In Cash -10.00M
YoY Change -6766.67%
FREE CASH FLOW
Cash From Operating Activities -$9.640M
Capital Expenditures -$360.0K
Free Cash Flow -$9.280M
YoY Change 17.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q3 advm Cash And Cash Equivalent Amortized Cost
CashAndCashEquivalentAmortizedCost
24866000
CY2017Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
24866000
CY2017Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
155031000
CY2017Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
154929000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
24000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
532000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1317000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
817000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-46000
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-988000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2936000
us-gaap Straight Line Rent
StraightLineRent
47000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-30024000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
201038000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
37738000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1488000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3449000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
39699000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
292000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
493000
advm Proceeds From Employee Stock Purchase Plan
ProceedsFromEmployeeStockPurchasePlan
83000
advm Proceeds From Employee Stock Purchase Plan
ProceedsFromEmployeeStockPurchasePlan
113000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
100000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
103000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
353000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-442000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-105000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-190457000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
9923000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
221348000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
231271000
advm Unpaid Deferred Offering Costs In Accounts Payable And Accrued Expenses
UnpaidDeferredOfferingCostsInAccountsPayableAndAccruedExpenses
200000
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
64845000
advm Fixed Assets In Accounts Payable Accrued Expenses And Other Current Liabilities
FixedAssetsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilities
148000
advm Fixed Assets In Accounts Payable Accrued Expenses And Other Current Liabilities
FixedAssetsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilities
771000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2006-07-17
dei Entity Information Date To Change Former Legal Or Registered Name
EntityInformationDateToChangeFormerLegalOrRegisteredName
2016-05-11
CY2017Q3 advm Cash And Cash Equivalent Gross Unrealized Loss
CashAndCashEquivalentGrossUnrealizedLoss
0
CY2017Q3 advm Cash And Cash Equivalent Gross Unrealized Gain
CashAndCashEquivalentGrossUnrealizedGain
0
CY2017Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
103000
CY2017Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2017Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
151769000
CY2017Q3 advm Available For Sale Securities Debt Maturities After Year One Through Three Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesAfterYearOneThroughThreeAmortizedCostBasis
28128000
CY2017Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
179897000
CY2017Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
151725000
CY2017Q3 advm Available For Sale Securities Debt Maturities After Year One Through Three Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterYearOneThroughThreeFairValue
28070000
CY2017Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
179795000
CY2017Q3 advm Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Temporary
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxTemporary
100000
CY2017Q3 advm Other Than Temporary Impaired Investments Available For Sale Securities
OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities
0
CY2017Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2017Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
179795000
CY2017Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7522000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6763000
CY2017Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4175000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2594000
CY2017Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000
CY2016Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
CY2017Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1628000
CY2016Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2570000
CY2017Q3 advm Accrued Preclinical Costs
AccruedPreclinicalCosts
805000
CY2016Q4 advm Accrued Preclinical Costs
AccruedPreclinicalCosts
1683000
CY2017Q3 advm Accrued Clinical And Development Process Costs
AccruedClinicalAndDevelopmentProcessCosts
669000
CY2016Q4 advm Accrued Clinical And Development Process Costs
AccruedClinicalAndDevelopmentProcessCosts
1142000
CY2017Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
725000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
894000
CY2017Q3 advm Accrued Contract Settlement
AccruedContractSettlement
2000000
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
235000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
162000
us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P4Y
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-05-08
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1400000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1300000
CY2017Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
0
us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
0
us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
0
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
CY2015Q3 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
3
CY2015Q4 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
1
CY2017Q1 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
13000000
advm Share Based Compensation Arrangement By Share Based Payment Award Options Closing Price Of Common Stock Intrinsic Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsClosingPriceOfCommonStockIntrinsicValueAmount
3.65
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1428000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.95
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3700000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7100000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2700000
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2942000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6839000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9852000
CY2017Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
10500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M25D
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8700000

Files In Submission

Name View Source Status
0001564590-17-022767-index-headers.html Edgar Link pending
0001564590-17-022767-index.html Edgar Link pending
0001564590-17-022767.txt Edgar Link pending
0001564590-17-022767-xbrl.zip Edgar Link pending
advm-10q_20170930.htm Edgar Link pending
advm-20170930.xml Edgar Link completed
advm-20170930.xsd Edgar Link pending
advm-20170930_cal.xml Edgar Link unprocessable
advm-20170930_def.xml Edgar Link unprocessable
advm-20170930_lab.xml Edgar Link unprocessable
advm-20170930_pre.xml Edgar Link unprocessable
advm-ex121_146.htm Edgar Link pending
advm-ex311_7.htm Edgar Link pending
advm-ex312_6.htm Edgar Link pending
advm-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending